Alimera Sciences Announces First Patient Treated With Commercially Available ILUVIEN®
ATLANTA, May 7, 2013 /PRNewswire/-- Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic ...
Alimera Sciences Reports First Quarter 2013 Financial Results
ATLANTA, May 9, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic ...
Ophthalmic Drugs: World Market Prospects 2013-2023
NEW YORK, April 30, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Ophthalmic Drugs: World Market Prospects 2013-2023 http://www.reportlinker.com/p0847305/Ophthalmic-Drugs-World-Market-Prospects-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ...
Alimera Sciences Announces New PDUFA Date For ILUVIEN®
ATLANTA, May 1, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic ...
pSivida Corp. Announces Commercial Launch of ILUVIEN® in Germany with First Patient Treated
pSivida Corp. , a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that ILUVIEN®, the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema , is now commercially available in Germany.
Alimera Sciences Announces ILUVIEN® Now Available In U.K.
ATLANTA, April 29, 2013 /PRNewswire/ -- Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ...
Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results
ATLANTA, May 3, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ...
pSivida Corp. Announces New ILUVIEN® PDUFA Date of October 17, 2013
pSivida Corp. , a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that the U.S. Food and Drug Administration acknowledged receipt of the resubmission of the New Drug Application for ILUVIEN® for treatment of chronic diabetic macular edema and stated that the resubmission was considered a complete, class 2 response to the ...
Alimera Sciences Secures $20 Million Debt Facility
ATLANTA, May 8, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic ...
Perelman School of Medicine at the University of Pennsylvania Names First Vice Dean for Diversity and Inclusion, Eve J ...
Prior to joining Penn Medicine, Dr. Higginbotham held numerous academic leadership roles, including Senior Vice President and Executive Dean for Health Sciences at Howard University and Dean and Senior Vice President for Academic Affairs at Morehouse School of Medicine in Atlanta.
|
